Rigel Pharmaceuticals | RIGL - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Agenus USD 323.49M 36.36M 2025-12
Amgen USD 24.96B 534M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 347.42M 151.94M 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Celldex Therapeutics USD 50.99M 4.53M 2025-12
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Heron Therapeutics USD 96.1M 6.39M 2025-12
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 717M 66M 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Ligand Pharmaceuticals USD 37.45M 6.91M 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Veracyte USD 56.11M 3.82M 2026-03